Detail of the clinical trial
| Title of the trial | Non-Comparative, Two-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous tem Cell Transplant (ASCT)Revised Protocol 01 incorporating Amendment 03 |
|---|---|
| EudraCT number | 2014-001509-42 |
| Protocol number | CA209-205 |
| Sponsor | Bristol-Myers Squibb International Corporation,Chaussée de la Hulpe 185,Brussels,1170 |
| Indications | Hemato-oncology |
| Diagnosis | Hodgkin Lymphoma |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2014 |
| Date of approval by Institute (SÚKL) | 12.9.2014 |
| Date of approval by EC | 16.10.2014 |
| Date of initiation CT in ČR | 17.12.2014 |
| Date of ending CT in ČR | |
| Notice | |
| Sites | Vseobecna fakultni nemocnice v Praze,I. interni klinika - klinika hematologie 1. LF UK a VFN v Praze,U Nemocnice 2,Praha 2,128 08 |
cz